Catherine A Hall

US Patent:

50136615, May 7, 1991

Filed:

Mar 15, 1989

Appl. No.:

7/323679

Inventors:

Robert S. Munford - Dallas TX
Catherine L. Hall - Dallas TX

Assignee:

The Board of Regents, The University of Texas System - Austin TX

International Classification:

C12N 918
A61K 31715
C12P 1926

US Classification:

435197

Abstract:

An acyloxyacyl hydrolase from the human promyelocyte cell line HL-60 has been found to specifically hydrolyze fatty acids from their ester linkages to hydroxy groups of 3-hydroxyfatty acids, the latter being being bound in turn to lipopolysaccharide glycosaminyl residues. The hydrolyzed fatty acids may include dodecanoic acid, tetradecanoic acid and hexadecanoic acid. This enzyme showed a molecular weight by gel exclusion chromatography between about 50,000 Daltons and about 70,000 Daltons, and a molecular weight by polyacrylamide gel electrophoresis with sodium dodecylsulphate, using reduced molecular weight standards, of approximately 54,000 to 60,000 Daltons. Altered bacterial lipopolysaccharide substantially without fatty acids bound in ester linkage to hydroxy groups of 3-hydroxyfatty acids covalently linked to a glucosaminyl moiety of lipopolysaccharide lipid A are produced. Since the structure of the lipid A moiety is highly conserved, acyloxyacyl hydrolase may act on lipopolysaccharide of many different pathogenic bacteria (for example Salmonella, Escherichia, Hemophilus, and Neisseria). Such altered bacterial lipopolysaccharide, having toxicity reduced more than immunostimulatory activity, may be therapeutically useful: (1) as vaccines to prevent Gram-negative bacterial diseases by inducing antibodies to lipopolysaccharide O-polysaccharide or R-core antigens, (2) as antidotes to treat or prevent Gram-negative bacterial sepsis ("septic shock"), or (3) as adjuvants to enhance formation of antibodies to other antigens.

US Patent:

49296043, May 29, 1990

Filed:

May 28, 1986

Appl. No.:

6/868428

Inventors:

Robert S. Munford - Dallas TX
Catherine L. Hall - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31715
C12P 1926
C12N 916
C07H 1310

US Classification:

514 53

Abstract:

An acyloxyacyl hydrolase from the human promyelocyte cell line HL-60 has been found to specifically hydrolyze fatty acids form their ester linkages to hydroxy groups of 3-hydroxyfatty acids, the latter being bound in turn to LPS glycosaminyl residues. The hydrolyzed fatty acids may include dodecanoic acid, tetradecanoic acid and hexadecanoic acid. This enzyme showed a molecular weight between about 50,000 daltons and about 70,000 daltons. Altered bacterial LPS substantially without fatty acids bound in ester linkage to hydroxy groups of 3-hydroxyfatty acids covalently linked to a glucosaminyl moiety of LPS lipid A are produced. Since the structure of the lipid A moiety is highly conserved, acyloxyacyl hydrolase may act on LPS of many different pathogenic bacteria (for example Salmonella, Escherichia, Hemophilus, and Neisseria). Such altered bacterial LPS, having toxicity reduced more than immunostimulatory activity, may be therapeutically useful: (1) as vaccines to prevent Gram-negative bacterial diseases by inducing antibodies to LPS 0-polysaccharide or R-core antigens, (2) as antidotes to treat or prevent gram-negative bacterial sepsis ("septic shock"), or (3) as adjuvants to enhance formation of antibodies to other antigens. The acyloxyacyl hydrolase itself may be therapeutically useful to detoxify endogenous LPS in patients with gram-negative bacterial diseases or to remove toxic LPS from therapeutic injectants.

US Patent:

52001849, Apr 6, 1993

Filed:

Jul 8, 1991

Appl. No.:

7/728763

Inventors:

Robert S. Munford - Dallas TX
Catherine L. Hall - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 3754
A61K 31715
C12N 918

US Classification:

424 9461

Abstract:

An acyloxyacyl hydrolase from the human promyelocyte cell line HL-60 has been found to specifically hydrolyze fatty acids from their ester linkages to hydroxy groups of 3-hydroxyfatty acids, the latter being bound in turn to LPS glycosaminyl residues. The hydrolyzed fatty acids may include dodecanoic acid, tetradecanoic acid and hexadecanoic acid. This enzyme showed a molecular weight by gel exclusion chromatography between about 50,000 Daltons and about 70,000 Daltons. Altered bacterial LPS substantially without fatty acids bound in ester linkage to hydroxy groups of 3-hydroxyfatty acids covalently linked to a glucosaminyl moiety of LPS lipid A are produced. Since the structure of the lipid A moiety is highly conserved, ac The U. S. Government may have rights in the present invention because the development was partially supported by NIH grant R01 AI18188 from the Department of Health and Human Services.

US Patent:

20110041253, Feb 24, 2011

Filed:

Apr 22, 2010

Appl. No.:

12/765201

Inventors:

Georgia G. Fiebrich - San Antonio TX, US
Catherine N. Hall - Castlerock CO, US

International Classification:

A47D 15/00

US Classification:

5663

Abstract:

A crib rail bumper is formed with a cushioning pad, a fabric cover dimensioned to encompass the pad, and reversible fastening means on opposite sides of the cover for securing the cover and pad to the crib rail. The reversible fastening means is preferably a reversible zipper. The crib rail bumper is compressible along the length dimension so as to encompass crib rails of varying lengths. The cushioning pad has a major length dimension, a minor width dimension, and a thickness dimension, the dimensions being selected for encompassing a crib rail. The reversible fastener allows multiple bumpers to be attached together to encompass wide rails or a plurality of rails.